Table 1 Baseline characteristics of the study population, ECG criteria and echocardiographic criteria before CRT implantation
No. = 67 | |
|---|---|
Age | |
Mean ± SD | 62.57 ± 5.84 |
Range | 52–74 |
Gender | |
Male | 39 (58.2%) |
Female | 28 (41.8%) |
BMI | |
Mean ± SD | 30.93 ± 4.54 |
Range | 24–46 |
Diabetes | |
Yes | 40 (59.7%) |
HTN | |
Yes | 44 (65.7%) |
CKD | |
eGFR > 60 | 57 (85.1%) |
eGFR 30–60 | 10 (14.9%) |
Cardiomyopathy | |
DCM | 34 (50.7%) |
ICM | 33 (49.3%) |
ACEI | |
Yes | 51 (76.1%) |
ARNI | |
Yes | 7 (10.4%) |
BB | |
Yes | 67 (100.0%) |
Diuretics | |
Yes | 64 (95.5%) |
MRAs | |
Yes | 44 (65.7%) |
SGLT2 inh | |
Yes | 8 (11.9%) |
QRS duration (msec) | |
Mean ± SD | 148.66 ± 22.42 |
Range | 130–200 |
Non-Strauss/Strauss | |
Non-Strauss | 37 (55.2%) |
Strauss | 30 (44.8%) |
Range | 5–15 |
Pre TR | |
Mild | 51 (76.1%) |
Moderate | 12 (17.9%) |
Severe | 4 (6.0%) |
Pre FAC | |
Normal | 57 (85.1%) |
Impaired | 10 (14.9%) |
Pre RVSP (mmhg) | |
Mean ± SD | 33.49 ± 9.25 |
Range | 30–60 |
Responders | |
Non-responders | 16 (24.2%) |
Responders | 50 (75.8%) |
GLS improvement | |
Median (IQR) | − 4 (− 6 to − 3) |
Range | − 11–0 |
GCS improvement | |
Median (IQR) | − 5 (− 7 to − 3) |
Range | − 10–0 |
Post TR | |
Mild | 50 (75.8%) |
Moderate | 12 (18.2%) |
Severe | 4 (6.1%) |
Post FAC | |
Normal | 57 (86.4%) |
Impaired | 9 (13.6%) |
Post RVSP | |
Mean ± SD | 34.38 ± 8.21 |
Range | 30–65 |
6-month hospitalization | |
Yes | 25 (37.3%) |
Mortality | |
Yes | 1 (1.5%) |